Choosing the right first-line treatment for childhood anxiety has long been a clinical guessing game, with families and clinicians left to navigate competing evidence without a clear roadmap. A rigorously designed trial now offers the most actionable sequencing data to date for one of the most prevalent mental health conditions in children and adolescents.
This 24-week sequential multiple assignment randomized trial (SMART) enrolled 316 youths aged 8–17 with DSM-5 anxiety disorders, notably drawn from primary care and mental health clinics serving populations with high sociodemographic disadvantage—a demographic historically underrepresented in anxiety research. Participants were first randomized to either fluoxetine or exposure-based cognitive-behavioral therapy (CBT) for 12 weeks. Those who failed to achieve remission were then rerandomized: continue and optimize the initial treatment, or escalate to combination therapy incorporating both modalities. Outcomes were measured using both youth- and parent-report versions of the SCARED (41-item Screen for Child Anxiety Related Emotional Disorders) and the Child Anxiety Impact Scale, providing a multidimensional picture of functional improvement.
The SMART design is particularly valuable here because it mirrors real-world clinical decision-making, where treatment courses are iterative rather than single-shot experiments. Prior landmark work—most notably the Child/Adolescent Anxiety Multimodal Study (CAMS)—established that combination sertraline plus CBT outperforms either alone at baseline. This trial builds on that foundation by asking the more practically urgent question: does the sequence and escalation strategy matter when first-line care is insufficient? The inclusion of a disadvantaged, comorbid population strengthens external validity considerably. Key limitations include the single-blind design, the 24-week observational window, and the use of fluoxetine rather than the better-studied sertraline, which may limit direct comparability with CAMS findings. Overall, this represents a clinically meaningful, potentially practice-changing contribution to pediatric mental health rather than incremental refinement.